8-K: Repare Therapeutics Announces Business Update and Year-End 2024 Financial Results, Prioritizes Clinical Programs and Reduces Workforce

Repare Therapeutics is focusing on Phase 1 clinical trials, reducing its workforce by 75%, and expects key clinical readouts in 2025 while extending its cash runway into late 2027.

Summary

• Repare Therapeutics reported its fourth quarter and full year 2024 financial results.
• The company is prioritizing its clinical programs and reducing its workforce by approximately 75% to extend its cash runway into late 2027.
• Key clinical readouts from Phase 1 trials of RP-3467 and RP-1664 are expected in Q3 and Q4 2025, respectively.
• The company had $152.8 million in cash, cash equivalents, and marketable securities as of December 31, 2024, compared to $223.6 million as of December 31, 2023.
• Revenue from collaboration agreements was nil for the three months ended December 31, 2024, and $53.5 million for the year, compared to $13.0 million and $51.1 million for the same periods in 2023.
• Net R&D expenses were $24.5 million and $115.9 million for the three and twelve months ended December 31, 2024, respectively.
• G&A expenses were $6.3 million and $29.7 million for the three and twelve months ended December 31, 2024, respectively.
• Net loss was $28.7 million, or $0.67 per share, and $84.7 million, or $2.00 per share, in the three and twelve-month periods ended December 31, 2024, respectively.

Sentiment

Score: 5

Explanation: The announcement contains both positive and negative elements. The focus on key clinical programs and extended cash runway are positive, but the workforce reduction and decreased cash reserves are concerning. The sentiment is neutral overall.

Positives

• The company's cash runway extends into late 2027 due to restructuring and portfolio re-prioritization.
• The company is focused on three ongoing Phase 1 clinical trials with readouts expected in 2025.
• Positive efficacy and safety data were reported from the Phase 1 MYTHIC gynecologic expansion clinical trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) at the recommended Phase 2 dose (RP2D) in patients with endometrial cancer (EC) and platinum-resistant ovarian cancer (PROC) in December 2024.
• Nearly half of patients with gynecologic cancers in the trial maintained progression-free survival (PFS) at 24 weeks, comparing favorably to PFS for current standard of care.

Negatives

• The company is reducing its workforce by approximately 75%.
• Cash reserves decreased from $223.6 million in 2023 to $152.8 million in 2024.
• The company intends to seek partnering opportunities for the Lunre+Camo program as a condition to further advancement of the program into pivotal development and will not continue to develop lunresertib or camonsertib in other studies.
• Revenue from collaboration agreements was nil for the three months ended December 31, 2024.

Risks

• The company's clinical development programs and future results could differ materially from expectations due to various risks and uncertainties.
• Unexpected safety or efficacy data observed during preclinical studies or clinical trials could negatively impact the company.
• Clinical trial site activation or enrollment rates that are lower than expected could delay progress.
• Changes in expected or existing competition and the regulatory environment could affect the company's prospects.
• Macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position.

Future Outlook

The company anticipates key clinical readouts from Phase 1 trials of RP-3467 and RP-1664 in Q3 and Q4 2025, respectively, and expects its cash runway to extend into late 2027.

Management Comments

• Our recently implemented re-structuring and the re-prioritization of our clinical portfolio meaningfully extends our cash runway into late 2027.
• We are now focused on three ongoing Phase 1 clinical trials with readouts expected in 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor; the POLAR trial evaluating our RP-3467 Pol ATPase inhibitor; and our ongoing MYTHIC trial evaluating lunresertib in combination with Debiopharm's WEE1 inhibitor, Debio 0123.
• Our progress with RP-3467 Poli is particularly promising.
• We believe we are leading the field with helicase Poli PARPi clinical combinations and look forward to sharing initial data by Q3 this year.

Industry Context

Repare Therapeutics is operating in the competitive precision oncology space, focusing on novel therapeutics targeting genomic instability and DNA damage repair. The company's strategy of prioritizing Phase 1 clinical programs and seeking partnerships aligns with the industry trend of focusing resources on promising assets and sharing development costs.

Comparison to Industry Standards

• Repare's focus on synthetic lethality and DNA damage repair pathways aligns with the strategies of companies like Artios Pharma and IDEAYA Biosciences.
• The workforce reduction of 75% is a significant restructuring, potentially impacting the speed of research and development compared to peers with more stable staffing levels.
• The cash runway extending into late 2027 provides a degree of financial stability, but the company's reliance on partnerships for further development of Lunre+Camo introduces uncertainty compared to companies with fully funded programs.
• The reported PFS data from the MYTHIC trial is promising, but further data and comparison to standard of care benchmarks are needed to fully assess its competitive advantage.

Stakeholder Impact

• Shareholders may be concerned about the workforce reduction and decreased cash reserves, but reassured by the extended cash runway and focus on key clinical programs.
• Employees are significantly impacted by the workforce reduction.
• Partners may be interested in the partnering opportunities for the Lunre+Camo program.
• Patients may benefit from the continued development of the company's clinical programs.

Next Steps

• The company expects initial clinical readout from Phase 1 RP-3467 (Polq ATPase/helicase inhibitor) POLAR trial in Q3 2025.
• The company expects initial clinical readout from Phase 1 RP-1664 (PLK4 inhibitor) LIONS trial in Q4 2025.
• The company intends to seek partnering opportunities for the Lunre+Camo program.

Key Dates